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Abstract 
Background: Allergen immunotherapy (AIT) may be prescribed for patients with allergic rhinitis (AR) induced by 
house dust mites (HDM) whether asthma is present or not. Current guidelines provide insufficient support for thera‑
peutic management strategy of these patients. Allergists however have long‑term experience with AIT. This study 
aims to describe the characteristics of the patients seen in clinical practice with HDM allergy and the process used to 
determine whether AIT should be initiated.
Methods: This was an observational, multicenter, prospective and cross‑sectional study, conducted in France from 
2013 to 2014 with a representative sample of allergy specialists. Any patient over 5 years of age with confirmed HDM 
allergy untreated with AIT within the last 12 months was eligible. Data were prospectively collected using physician 
and patient questionnaires.
Results: A total of 1589 patients (60 % adults, 40 % children) were included by 195 randomly selected allergists. A 
subgroup of 1212 patients (median age: 22 years; 52 % women) were selected for AIT treatment with a median time 
of AR diagnosis of 3 years. Amongst these, 59 % had a moderate to severe persistent AR according to AR and its 
Impact on Asthma guidelines, 57.5 % were polysensitized, and 56.5 % also suffered from conjunctivitis (median rhinitis 
total symptom score: 11). Asthma was present in 42 % of patients, and was controlled according to Global Initiative for 
Asthma guidelines in 62 % of patients. The asthma control questionnaire score was 1–1.5 in 20 % and ≥1.5 in 37 % of 
patients. A total of 57 % patients received a prescription of ≥2 medications (mainly antihistamines). Usual daily activi‑
ties and sleep quality were slightly‑to‑moderately impaired as the mean rhinoconjunctivitis quality of life question‑
naire score was 2.7 ± 1.5. The major driver of AIT prescription is AR uncontrolled by previous medications leading to 
patient dissatisfaction.
Conclusions: HDM‑AR associated conjunctivitis was present in 60 % and asthma in 40 % of cases. In >40 % of these 
cases, asthma was inadequately controlled at the start of AIT.
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Background
The prevalence of allergic rhinitis (AR) is increasing 
and is currently estimated to be 10–20 % of the popula-
tion worldwide [1]. House dust mites (HDM) are one of 
the main causes of perennial AR [2]. The prevalence of 
HDM allergen sensitization varies from 65 to 130 mil-
lion individuals in the general population worldwide 
[3]. AR is associated with a high symptom burden and 
impaired health-related quality of life (HRQoL), sleep [4] 
and productivity at school or work, with a negative soci-
oeconomic impact caused by absenteeism and passive 
presenteeism [5–7]. Patients with HDM allergy typically 
present with symptoms of moderate-to-severe rhinitis. 
In addition, rhinitis and asthma often coexist in the same 
patients because AR is associated with allergic asthma 
(AA) in nearly 50 % of cases [8, 9].
Allergen immunotherapy (AIT) represents a valid 
therapeutic alternative to HDM avoidance or for patients 
who experienced symptomatic medication failure or have 
fears and/or developed side effects to other therapies 
[10]. In recent years, many randomized, placebo-con-
trolled trials have shown that sublingual immunother-
apy (SLIT) is effective at reducing symptoms of AR with 
a well-tolerated safety profile in children, adults and 
elderly, which is not optimally controlled by pharmaco-
logic medication and HDM avoidance [11–13]. A meta-
analysis also reported a statistically significant reduction 
in symptoms and medication requirements by AIT com-
pared with placebo [12, 13].
However, the use of AIT in the therapeutic manage-
ment of both AR and AA needs to be better clarified in 
everyday practice because current guidelines, especially 
for asthma [14], do not provide sufficient support for 
AIT. We need to understand the real life use of AIT and 
to bridge the gap between real life and guidelines using 
data from randomized controlled trials. Respiratory aller-
gic diseases should be better phenotyped for AIT indica-
tions. The severity level of AA as well as medications and 
strategies for symptom control and risk reduction were 
defined in the latest Global Initiative for Asthma (GINA) 
guidelines [14]. In control-based AA management, phar-
macological and non-pharmacological treatments are 
adjusted in a continuous cycle that involves assessment, 
treatment and review. For example, the level of AA symp-
tom control depends on the frequency of daytime symp-
toms, frequency of relief needed for symptom control, 
night waking caused by disease, and activity limitation 
[14]. Similarly, the AR and its Impact on Asthma (ARIA) 
guidelines initiated during a World Health Organiza-
tion (WHO) workshop in 1999, published in 2001, and 
last updated in 2010, classified AR as mild/moderate-
to-severe and intermittent/persistent [1]. Although this 
classification underlines the close relationship between 
rhinitis and AA, physicians are faced with various treat-
ment options for the management of AR [15] and AA 
separately, contributing to possible variations in clinical 
practice. Patients with mild AR are unlikely to consult a 
physician, and therefore, specialists usually see moder-
ate-to-severe AR for which the guidelines are not com-
plete. Moreover, only 62  % of specialists were reported 
to always or frequently apply the ARIA treatment algo-
rithms in the daily management of AR patients [16]. 
Other limitations have been described in the literature 
as these guidelines do not take into account previous and 
current treatment, they include a heterogeneous group of 
moderate-to-severe patients, and provide poor guidance 
on patient management [17]. Therefore, the development 
of a control-based classification in AR similar to that in 
the GINA recommendations for asthma would be useful 
for clinicians [18]. The identification of a particular sub-
group of patients for whom AIT initiation is decided by 
experienced allergists might contribute to the implemen-
tation of a stepwise approach.
The present real-life study aims to (1) describe the 
severity of symptoms, and control levels of AR and AA 
during the past month before inclusion in a large patient 
population consulting for HDM-AR and prescribed AIT, 
(2) identify homogeneous sub-groups by control levels 
to better guide AIT use in a therapeutic strategy, and (3) 
describe the benefits experienced by patients with previ-
ous symptomatic medication(s) of AR and expectations 
of AIT.
Methods
Study design
This was an epidemiological, observational, multicenter, 
national, prospective and cross-sectional study. This 
3-month study was carried out in France from October 
2013 to March 2014. A total of 1600 French allergy spe-
cialists (allergists, ear, nose and throat specialists, pedia-
tricians, pulmonologists) randomly selected from a large 
sample of physicians participated in the study. Each phy-
sician was asked to include nine consecutive patients 
who had been seen for HDM allergy. As AIT is usually 
initiated in approximately 66  % of cases [19] in French 
allergist practices, AIT was expected to be prescribed in 
six out of nine patients. Physicians saw their patients as 
usual over the course of consultations. The study did not 
affect patient diagnostic or therapeutic management.
Ethical considerations
The study was conducted in compliance with the Decla-
ration of Helsinki, Good Epidemiological/Pharmacoepi-
demiological study guidelines, good practice guidelines 
and local regulations. All data were collected anony-
mously. As the study did not fall within the scope of the 
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public health code (Article L1121-1), approvals from 
Ethics Committees and the French Health Authority 
(ANSM) were not required.
Patients
Ambulatory male or female patients, aged at least 5 years, 
seen in usual consultation with HDM allergy (confirmed 
by skin testing and/or positive measurement of specific 
immunoglobulins IgE) with clinical manifestations of 
AR, able to complete a questionnaire (or by one of the 
parents or legal representative for minors), informed 
and willing to participate in the study were selected for 
inclusion. Patients treated with HDM-AIT within the 
last 12 months at the time of enrollment were excluded 
from participation. All patients (or a parent or legal rep-
resentative) were informed by the physician on the study 
purpose, and signed an informed consent form before 
participation.
Collected data
Data were prospectively collected using a case report 
form for each patient on the day of the consultation. 
Patient demographic and clinical characteristics (includ-
ing medical history, frequency and intensity of AR symp-
toms according to the ARIA classification, rhinitis total 
symptom score for sneezing, runny nose, itchy nose, 
nasal congestion, watery eyes and itchy eyes (0–18 range 
of scores, the upper value of 18 indicating permanent 
very severe levels for all six symptoms), comorbidities, 
and if applicable, stage and level of AA according to the 
GINA classification were collected. The total nasal symp-
tom score comprised four nasal symptoms (0–12 range). 
Last available forced expiratory volume in one second 
(FEV1) value, any drug consumption for AR and AA in 
the previous 12 months, overall assessment of physician 
and patient satisfaction towards symptomatic medica-
tions were listed. AR and AA control data by current 
medications with 10 cm visual analog scales (VAS) were 
confidentially recorded by the physician (0: uncontrolled 
to 10: controlled).
In addition, a self-report patient questionnaire was 
completed after consultation. It comprised control test-
ing of AR using a five-item self-assessment AR con-
trol test (ARCT) developed for assessing the control 
of AR [20] (a score of 20 being the cut-off for poor vs 
well-controlled rhinitis), severity and control level of 
rhinoconjunctivitis symptoms using a 10-cm VAS, rhi-
noconjunctivitis quality of life questionnaire (RQLQ) for 
evaluating AR impact, symptoms of rhinoconjunctivitis 
(including their severity, and level of control), asthma 
control questionnaire (ACQ) for asthmatics, benefits 
(patient benefit questionnaire, PBQ) and expectations 
(patient needs questionnaire, PNQ) towards concomitant 
symptomatic medications taken the previous month and 
the new treatment, respectively [21].
Statistics
Statistical analysis was performed on the data from 
all eligible informed patients meeting the inclusion 
criteria, having filled in a self-administered question-
naire, and receiving a completed prescription at the 
end of the consultation. This analysis was performed 
on all patients and by patient age as follows: children 
(5–17  years) and adults (≥18  years). Categorical vari-
ables were compared using the Chi squared test or 
Fischer’s exact test, and continuous variables were 
compared using the Student’s t test or non-parametric 
test (Mann–Whitney U-test). Correlations between 
variables were analyzed using Spearman’s test. Cluster 
analysis based on classifications and usual scores [22] 
was performed to develop a useful tool in clinical prac-
tice by using nine variables defining demographic and 
clinical patient characteristics. All statistical hypothesis 
tests were performed at alpha  =  5  % level of signifi-
cance using SAS® software (version 9.2; SAS® Institute 
Inc., Cary, NY, USA). No adjustment for multiplicity 
was performed because this was an observational and 
exploratory study where data were collected with an 
objective but not with a pre-specified key hypothesis. 
The calculation of the number of subjects needed was 
determined to be 20  % of patients with symptoms of 
mild AR with an accuracy of 5–6 % in the strata of asth-
matic and non-asthmatic patients; no prior assump-
tions were made. Inferential results of this study cannot 
be used as evidence but can only be considered as sup-
portive to generate new hypotheses.
Results
Patients
A total of 195 specialists included 1589 patients in the 
study, corresponding to the analysis population. Of these, 
1212 patients (76.3  %) received a prescription for AIT. 
The population consisted of 938 adults and 625 children, 
with a slight predominance of female adults and male 
children (Table  1). The mean age was 24  years (range: 
4–76  years). Overall, 38.6  % of patients had AR associ-
ated with AA. The mean duration of AR since diagno-
sis was 5.4 ±  7.3  years in patients selected for AIT and 
5.3 ± 7.0 years in those not selected.
Nearly all patients (97.2  %) were skin prick tested the 
day of recruitment. HDM specific IgE was measured in 
57.7 % of patients, and more frequently in patients who 
initiated AIT treatment (59  % of adults and 64.4  % of 
children). A total of 863 patients (56.2  %) were sensi-
tive to at least one other allergen and 673 (43.8 %) were 
sensitive to HDM allergens only. Other major allergens 
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in polysensitized patients were grass pollen (55.8 %) and 
dander (43.1 %).
A total of 1187 patients (74.7 % of all included patients, 
97.9 % of patients with AIT prescription) were prescribed 
SLIT. Among patients in the AIT group, 5.9 % were pre-
scribed multiple AIT. Other major allergens given to the 
patients were grass (8.3 % of adults and 6.1 % of children) 
and tree pollen (6.1 and 1.9 %, respectively). Overall, the 
planned maintenance phase was 12  months/year. The 
daily dose was 300 IR/mL for most patients (98.1  % of 
adults and 97.1 % of children) and seven times per week 
for the majority of patients (84.5 and 81.4 %, respectively).
AR characteristics according to severity (ARIA 
classification) and control
The characteristics of AR according to the ARIA clas-
sification are presented in Fig.  1. Overall, moderate-
to-severe persistent AR was the most common type of 
rhinitis (59.2  %). Regardless of patient age, the patients 
selected for AIT experienced more frequent moderate-
to-severe persistent AR than those not selected for AIT 
(p < 0.001). The most common clinical symptoms of rhi-
nitis considered by the physician to occur very frequently 
included rhinorrhea (38.2 %), nasal obstruction (37.9 %), 
and sneezing (37.2  %). Intensity of the most frequent 
clinical symptoms was mainly moderate. The inten-
sity of AR clinical symptoms assessed by patients using 
the mean VAS score was significantly higher in patients 
selected for AIT than those not selected for AIT-treat-
ment (4.6 ± 2.1 vs 4.0 ± 2.1 cm, respectively; p < 0.001). 
This trend was confirmed for each AR clinical symptom 
regardless of patient age except for sneezing and nasal 
obstruction in children for whom the mean VAS score 
was comparable in both groups. The median rhinitis 
Table 1 Demographic and  clinical characteristics at  time 
of consultation
AIT
(N = 1212)
No-AIT
(N = 377)
Total
(N = 1589)
Age (years)
 Children (N = 625)
  N available 489 136 625
  Missing 0 0 0
  Mean (SD) 10.7 ± 3.6 11.3 ± 3.6 10.8 ± 3.6
  Median 10 12 11
  Q1, Q3 8, 14 8, 14 8, 14
  Range 4, 17 4, 17 4, 17
 Adults (N = 938)
  N available 709 229 938
  Missing 0 0 0
  Mean (SD) 32.5 ± 10.4 34.0 ± 12.8 32.9 ± 11.1
  Median 31 30 31
  Q1, Q3 24, 38 24, 41 24, 39
  Range 18, 76 18, 74 18, 76
 Total (N = 1589)a
  N available 1198 365 1563
  Missinga 14 12 26
  Mean (SD) 23.6 ± 13.6 25.5 ± 15.1 24.1 ± 14.0
  Median 22 24 22
  Q1,Q3 12, 33 14, 35 12, 33
  Range 4, 76 4, 74 4, 76
Gender (n,  %)
 Children (N = 625)
  N available 488 136 624
  Missing 1 0 1
  Male 298 (61.1 %) 79 (58.1 %) 377 (60.4 %)
  Female 190 (38.9 %) 57 (41.9 %) 247 (39.6 %)
 Adults (N = 938)
  N available 709 229 938
  Missing 7 7 14
  Male 274 (38.6 %) 99 (43.2 %) 373 (39.8 %)
  Female 435 (61.4 %) 130 (56.8 %) 565 (60.2 %)
 Total (N = 1589)a
  N available 1204 370 1574
  Missinga 8 7 15
  Male 575 (47.8 %) 182 (49.2 %) 757 (48.1 %)
  Female 629 (52.2 %) 188 (50.8 %) 817 (51.9 %)
Duration of AR since diagnosis (years)
 Children (N = 625)
  N available 451 123 574
  Missing 38 13 51
  Mean 2.7 ± 2.9 2.6 ± 2.9 2.7 ± 2.9
  Median 2.0 1.0 2.0
  Q1, Q3 0.5, 4.0 0.5, 4.0 0.5, 4.0
  Range 0.0, 16.0 0.0, 12.9 0.0, 16.0
 Adults (N = 938)
  N available 678 221 899
Table 1 continued
AIT
(N = 1212)
No-AIT
(N = 377)
Total
(N = 1589)
  Missing 31 8 39
  Mean 7.2 ± 8.7 6.9 ± 8.1 7.1 ± 8.5
  Median 4.0 3.0 3.0
  Q1, Q3 1.0, 10.0 0.8, 10.0 1.0, 10.0
  Range 0.0, 55.0 0.0, 40.0 0.0, 55.0
 Total (N = 1589)a
  N available 1136 353 1489
  Missinga 76 24 100
  Mean 5.4 ± 7.3 5.3 ± 7.0 5.4 ± 7.2
  Median 3.0 2.0 2.0
  Q1, Q3 0.8, 7.0 0.5, 9.0 0.7, 7.0
  Range 0.0, 55.0 0.0, 40.0 0.0, 55.0
a The total population corresponding to the analysis population (N = 1589) 
included patients with missing age (N = 26)
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total symptom score was 11 out of 18 in the group of 
patients selected for AIT compared with nine in those 
not selected for AIT (p < 0.001), corresponding to more 
nasal symptoms (median total nasal symptom score, total 
nasal symptom score = 8 versus 7 out of 12, respectively; 
p  <  0.001) than ocular symptoms. These symptoms of 
AR were considered to be moderately-to-severely both-
ersome in everyday life within the 12 last months of 
75.8  % of patients selected for AIT compared to 56.8  % 
not selected for AIT (p < 0.001). Moreover, according to 
the results from the RQLQ, patients were more bothered 
by nasal symptoms (mean score: 3.4  ±  1.4) than ocu-
lar symptoms (1.7 ±  1.6). The effect of AR on practical 
problems and activities/sleep was moderate (mean score: 
3.3 ± 1.6 and 2.7 ± 1.5, respectively).
Regarding the level of AR symptom control, the median 
VAS scores showed that AR was moderately controlled 
in both groups with a statistically significant difference 
(4.5 in the group selected for AIT vs 6.2 in the group 
not selected, p < 0.001). Similarly, the mean ARCT score 
was significantly higher in the group of patients selected 
for AIT (17.9  ±  4.0) than in the group not selected 
(16.7  ±  4.3) (p  <  0.001). A moderate correlation was 
found between both tools, ARCT and VAS for AR con-
trol (r = 0.37; p < 0.0001).
Associated allergy/hypersensitivity conditions
Overall, 1189 patients (76.1  %) had at least one allergy/
hypersensitivity co-morbid condition (79.8 % in the AIT 
group vs 64.3 % in the no-AIT group; p < 0.001). The asso-
ciated conditions were conjunctivitis (53.8  %) (Table  2), 
followed by sinusitis and eczema (14.9  % respectively), 
and urticaria (7.1  %). Conjunctivitis occurred more fre-
quently in patients selected for AIT than other patients 
(very frequent: 20.9  vs  8.2  %; fairly frequent: 36.5 vs 
32.3  %, respectively). The conjunctivitis intensity was 
moderate and severe in selected AIT-patients (46.9 and 
19.7  % respectively), but mild (53.7  %) in patients not 
selected for AIT.
Associated AA was observed in 41.8  % (507/1212) 
of patients selected for AIT compared with 28.1  % 
(106/377) of non-selected patients (p < 0.001) (Table 2). 
FEV1 was ≥80 % in the majority of cases (mean: 84.4 %), 
varying between 70 and 79 % in 11.7 %, 60–69 % in 3 %, 
and 50–59  % in 0.9  %. Intensity of AA was persistent 
mild to moderate in most cases (93 vs 95.1 % in patients 
selected and not selected for AIT, respectively) accord-
ing to the GINA classification. In the opinion of the 
study physicians, AA was considered partly controlled in 
32 % in those selected for AIT vs 27.7 % in not selected 
or was uncontrolled in few cases (6.4 % selected for AIT 
vs 6.9  % not selected, respectively). The distribution of 
patients with AA in treatment steps 1, 2, 3, 4, and 5 was 
34.7, 26.9, 31.4, 6.7 and 0.2 % of patients who started AIT, 
respectively, with no marked differences compared with 
patients not selected for AIT (31.1, 35.0, 29.1, 2.9 and 
1.9 %, respectively) (Table 3). However, there were more 
asthmatics in the group selected for AIT treatment who 
7.6
19.9
5.3
21.9
6.2
21.7
24.8
28.7
14.8
21.1
18.9
23.5
14.5
16.2
16.5
19.3
15.7
18.4
53.1
35.3
63.5
37.7
59.2
36.4
0
20
40
60
80
100
AIT (N=489) No-AIT (N=136) AIT (N=709) No-AIT (N=229) AIT (N=1,212) No-AIT (N=377)
Children Adults Total
Mild intermient Mild persistent Moderate to  severe intermient Moderate to severe persistent
Percentage (%)
p<0.001 p<0.001 p<0.001
Fig. 1 Severity of AR according to the ARIA guidelines. Chi‑squared test. AIT patients selected for HDM AIT, No-AIT patients not selected for AIT
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were reported to be uncontrolled by the ACQ question-
naire (ACQ ≥1.5: 36.8  % in the group selected for AIT 
vs 23.8 % in the group not selected for AIT, respectively) 
but this difference was not statistically significant (Fig. 2). 
The VAS score for AA control decreased in parallel with 
more uncontrolled AA (Table  3) with a significant cor-
relation between both VAS and ACQ scores (Spearman 
ratio  =  −0.535; p  <  0.0001). The level of AA symptom 
control was comparable in both groups as shown by 
the mean ACQ scores (1.3  ±  0.9 in the group selected 
for AIT vs 1.2 ±  1.0 in the group not selected for AIT; 
p  =  non-significant [NS]) and the mean VAS scores 
(7.5 ± 2.7 vs 7.6 ± 2.7; p = NS).
Previous and concomitant symptomatic medications
Within the last 12  months, monotherapy for AR was 
received by 41.8 % of patients, bitherapy in 37.8 % and ≥3 
medications in 12.7 % (Fig. 3). At the time of HDM-AIT 
initiation, 1497 patients (98.9 %) were prescribed symp-
tomatic medications: 39.6 % of all included patients were 
treated with monotherapy, and 42.1 and 13.4 % received 
2 or  ≥3 symptomatic medications, respectively. The 
number of symptomatic medications received was simi-
lar irrespective of the patient age and selected group 
(AIT vs no-AIT) (Fig.  3). The main prescribed symp-
tomatic medications were oral antihistamines (95.5  %) 
(Fig. 4). Treatment with systemic corticoids was uncom-
mon (≤5 % of patients). Nearly all AA patients (97.7 %) 
received at least one medication for AA. At the time 
of AIT initiation, prescriptions with short acting beta-
agonists (SABA) were renewed in 81.6  % in patients 
with AA. New prescriptions with SABA (7.3  %) and/or 
long acting beta-agonists (3.9 %) were limited. The same 
was observed for oral and inhaled corticoids, and for 
anti-leukotrienes.
Physician and patient expectations and satisfaction 
of previous medications
Regardless of the group of patients, 94.5 % of physicians 
reported they would like an improvement of AR symp-
toms and quality of life (QoL). The main expectations 
stated by about 90  % of patients that were considered 
to be significant to very significant towards their new 
prescribed treatments were the relief of symptoms, 
no nasal congestion or runny nose, ease of breathing 
through the nose, and no sneezing fits, regardless of the 
group asked (Table 4). Overall, these expectations were 
significantly more frequent in patients selected for AIT 
than others. More than 75 % of patients highlighted an 
interest in the ease of use with a statistically significant 
difference between both groups: 84.7  % in the group 
selected for AIT vs 76.9  % in the group not selected 
(p = 0.006).
Over 33  % of patients considered that symptomatic 
medications for AR used during the last month were not 
helpful for almost all factors described in the PBQ such 
Table 2 Sensitization profile and associated allergic condi-
tions at time of consultation
a The total population corresponding to the analysis population (N = 1589) that 
included patients with missing age (N = 26)
AIT
(N = 1212)
No-AIT
(N = 377)
Total
(N = 1589)
Patients with polysensitization (n,  %)
 Children (N = 625)
  N available 476 135 611
  Missing 13 1 14
  n (%) 242 (50.8 %) 73 (54.1 %) 315 (51.6 %)
 Adults (N = 938)
  N available 686 222 908
  Missing 23 7 30
  n (%) 425 (62.0 %) 111 (50.0 %) 536 (59.0 %)
 Total (n = 1589)a
  N available 1170 366 1536
  Missinga 42 11 53
  n (%) 673 (57.5 %) 190 (51.9 %) 863 (56.2 %)
Patients with asthma (n,  %)
 Children (N = 625)
  N available 489 136 625
  Missing 0 0 0
  n (%) 231 (47.2 %) 48 (35.3 %) 279 (44.6 %)
 Adults (N = 938)
  N available 709 229 938
  Missing 0 0 0
  n (%) 274 (38.6 %) 54 (23.6 %) 328 (35.0 %)
 Total (N = 1589)a
  N available 1212 377 1589
  Missing 0 0 0
  n (%) 507 (41.8 %) 106 (28.1 %) 613 (38.6 %)
Patients with conjunctivitis (n,  %)
 Children (N = 625)
  N available 477 132 609
  Missing 12 4 16
  n (%) 259 (54.3 %) 50 (37.9 %) 309 (50.7 %)
 Adults (N = 625)
  N available 687 225 912
  Missing 22 4 26
  n (%) 398 (57.9 %) 108 (48.0 %) 506 (55.5 %)
 Total (N = 1589)a
  N available 1176 369 1545
  Missing 36 8 44
  n (%) 664 (56.5 %) 167 (45.3 %) 831 (53.8 %)
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as leading a normal sexual life, feeling less depressed, less 
irritable, or less tired/groggy (Table  5). However, there 
were some exceptions because 62  % of patients judged 
that medications had a somewhat to very important sup-
port in relieving symptoms.
Cluster analysis
A cluster analysis was performed on 1456 patients with 
AR having completed the questionnaires and without 
major deviation to the protocol to understand the aller-
gists’ criteria to prescribe AIT.
Table 3 Control of asthma assessed by the physician using VAS, ACQ score and GINA classification
** Kruskal–Wallis test or Fisher’s exact test
a The total population corresponding to the whole population of asthmatics (N = 613) that included patients with missing age (N = 6)
ACQ <1 
N = 164
1–1.5 
N = 78
≥1.5 
N = 128
p value**
Control of asthma (VAS)
 N available 164 78 128
 Mean ± SD 8.64 ± 1.79 7.41 ± 2.63 6.10 ± 2.67 <0.001
 Median 9.4 8.3 6.5
 Min, Max 1.8, 10.0 0.8, 10.0 0.6, 10.0
GINA classification Controlled
N = 366
Partly controlled
N = 184
Uncontrolled
N = 38
p value**
Control of asthma (VAS)
 N available 366 184 38
 Mean ± SD 8.8 ± 1.8 5.8 ± 2.0 2.5 ± 2.2 <0.001
 Median 9.4 6.2 1.8
 Min., Max 0.0, 10.0 0.8, 9.3 0.0, 8.4
Treatment steps according 
to GINA classification
AIT No-AIT Total p value**
Children (N = 279)
 N available 224 46 270
 Missing 7 2 9
 Step 1 67 (29.9 %) 13 (28.3 %) 80 (29.6 %) 0.102
 Step 2 70 (31.3 %) 15 (32.6 %) 85 (31.5 %)
 Step 3 73 (32.6 %) 15 (32.6 %) 88 (32.6 %)
 Step 4 14 (6.3 %) 1 (2.2 %) 15 (5.6 %)
 Step 5 0 (0.0 %) 2 (4.3 %) 2 (0.7 %)
 N available 224 46 270
Adults (N = 328)
 N available 265 53 318
 Missing 9 1 10
 Step 1 103 (38.9 %) 18 (34.0 %) 121 (38.1 %) 0.502
 Step 2 61 (23.0 %) 18 (34.0 %) 79 (24.8 %)
 Step 3 81 (30.6 %) 15 (28.3 %) 96 (30.2 %)
 Step 4 19 (7.2 %) 2 (3.8 %) 21 (6.6 %)
 Step 5 1 (0.4 %) 0 (0.0 %) 1 (0.3 %)
Total (N = 613)a
 N available 490 103 593
 Missing 17 3 20
 Step 1 170 (34.7 %) 32 (31.1 %) 202 (34.1 %) 0.066
 Step 2 132 (26.9 %) 36 (35.0 %) 168 (28.3 %)
 Step 3 154 (31.4 %) 30 (29.1 %) 184 (31.0 %)
 Step 4 33 (6.7 %) 3 (2.9 %) 36 (6.1 %)
 Step 5 1 (0.2 %) 2 (1.9 %) 3 (0.5 %)
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Three clusters with statistically significant differences 
were identified: age, sex, frequency of associated AA, 
AR severity and level of control, ARCT score, physician/
patient satisfaction rate, and prescription of AIT (Table 6). 
Patients in cluster 1 had moderate and partly controlled 
AR. The majority of patients in cluster 2 experienced mild 
and well controlled AR, while those in cluster 3 who were 
mostly females (61.6  %) and older than in other clusters 
(median age: 27 years) had very severe and uncontrolled 
AR. AIT was more often prescribed in patients belong-
ing to cluster 3 (82.8  %) compared to clusters 1 and 2 
(78.6 and 61.8 % respectively, p < 0.001).
Discussion
The findings of this study reveal the profile of patients 
being initiated on HDM AIT-treatment in allergist 
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Table 4 Patient needs at time of consultation
Analysis of the patient needs questionnaires (PNQ) completed on the day of the consultation, corresponds to the needs of the patient (i.e. what he/she expected from 
a new therapeutic management of disease by her/his physician). Patient needs are ordered by decreasing importance in the total population. Needs are rated using a 
six-point scale from ‘not concerned’ to ‘very important’
** Chi squared test or Fisher’s exact test
a Percentage of patients with needs corresponding to ‘quite important’ to ‘very important’ at allergen immunotherapy initiation
Percentage of quite/very important responsesa p value**
AIT (N = 1083), % No-AIT (N = 335), % Total (N = 1418), %
To be relieved of all symptoms 96.1 92.4 95.2 0.020
To no longer have a runny or blocked nose 94.9 92.2 94.3 0.179
To be able to breathe through my nose more freely 92.1 89.4 91.5 0.296
To not have sneezing impulses 87.6 83.9 86.7 0.176
To have a treatment which is easy to use 84.2 76.9 82.5 0.006
To not experience eye, nose or palate stinging anymore 82.0 73.8 80.1 0.003
To have confidence in the therapy 82.8 70.2 79.9 <0.001
To experience more enjoyment of life 76.7 66.0 74.2 <0.001
To be able to sleep better 75.2 62.4 72.2 <0.001
To be able to concentrate better at work 73.1 66.0 71.4 0.042
To be able to stay outdoors without symptoms 72.8 66.7 71.3 0.033
To be able to engage in normal leisure activities 73.9 61.7 71.0 <0.001
To have no fear that the disease will become worse 72.4 61.2 69.7 0.001
To feel less tired or groggy 71.8 62.6 69.6 <0.001
To be more productive in everyday life 69.6 60.6 67.5 0.009
To not have burning or watery eyes anymore 67.6 57.2 65.2 0.002
To reduce the frequency of visits to the physician 68.3 54.3 65.0 <0.001
To feel more comfortable in public 58.4 54.2 57.4 0.229
To feel less burdened in your relationship 59.2 51.7 57.4 0.057
To spend less time on daily treatment 57.5 51.1 56.0 <0.001
To have fewer side effects 55.5 46.7 53.5 0.019
To feel less irritated 54.7 44.8 52.3 0.007
To have fewer out‑of‑pocket treatment expenses 53. 46.1 51.6 0.012
To feel less depressed 44.9 35.8 42.8 0.002
To be able to have a normal sex life 41.5 38.6 40.8 0.532
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practices in France. The major driver of AIT prescription 
is an AR uncontrolled by previous medications leading to 
patient dissatisfaction. At treatment initiation, patients 
were young. The management takes into account comor-
bidities, such as AA and rhinoconjunctivitis [23]. Our 
results were consistent with a previous study [24] show-
ing that more children than adults experience AR with 
AA (44.6 vs 35 %). Moreover, the occurrence of AA dou-
bled the likelihood of selecting for HDM AIT treatment 
in our study. The results suggest that the severity and 
level of control differed between patients selected or not 
for AIT treatment. Of note, AA was insufficiently con-
trolled in approximately 33 % of patients before starting 
AIT, and the QoL was particularly impacted in patients 
selected for AIT. Uncontrolled AA does not limit AIT 
prescription (38.4  % of inadequately controlled patients 
in the group selected for AIT), probably because it was 
reported that AIT is effective in the treatment of AR and 
asthma for HDM sensitivity [25]. Therefore, the mutual 
evaluation of AR and AA control is needed before pre-
scribing an appropriate treatment.
HDM AIT solution was prescribed in almost all 
patients with a sublingual concentration of 300 IR/mL 
every day, which was reported to have the best benefit-
risk profile in clinical practice [26]. Non-compliance to 
the treatment may have a strong impact on the condition 
of patients suffering from chronic disease. A systematic 
review of publications that assessed adherence showed 
that 55–82 % of patients discontinued SLIT before com-
pleting the recommended treatment duration of 3 years 
[27, 28]. The main causes of non-adherence may be linked 
to lower socioeconomic status, younger age [28], and cost 
of treatment [29]. However, one study that attempted 
to test an educational intervention with a strict follow-
up showed a significant improvement in SLIT adher-
ence [30]. Concerning patient satisfaction, about 66 % of 
Table 5 Patient benefits related to medications for AR taken during the past month at time of consultation
Analysis of the patient benefits questionnaires (PBQ) completed the day of the consultation correspond to the benefits that the patient expressed relative to the 
previous symptomatic therapeutic management for AR. Patient benefits are ordered by decreasing importance of the corresponding need. Treatment-related benefits 
are rated using a five-point scale from ‘did not help at all’ to ‘helped a lot’
** Chi squared test
a Percentage of patients with benefits achieved by treatments for AR from ‘rather helped’ to ‘helped a lot’ at allergen immunotherapy initiation
Percentage of patients helped rather/a lota p value**
AIT (N = 1012), % No-AIT (N = 301), % Total (N = 1313), %
To have a treatment which is easy to use 71.6 69.8 71.2 0.541
To have confidence in the therapy 62.9 61.4 62.6 0.635
To be relieved of all symptoms 60.3 67.2 61.9 0.031
To not have sneezing impulses 58.3 62.2 59.2 0.230
To be able to breathe through my nose more freely 55.8 66.2 58.2 0.001
To no longer have a runny or blocked nose 56.5 63.0 58.0 0.049
To experience more enjoyment of life 58.3 53.9 57.3 0.188
To be able to engage in normal leisure activities 57.5 53.4 56.6 0.219
To not experience eye, nose or palate stinging anymore 53.5 56.6 54.2 0.361
To be able to stay outdoors without symptoms 52.8 56.5 53.6 0.264
To be able to sleep better 53.5 48.8 52.5 0.156
To reduce the frequency of visits to the physician 50.4 48.4 49.9 0.566
To be able to concentrate better at work 49.3 50.3 49.6 0.763
To have no fear that the disease will become worse 49.2 49.0 49.1 0.950
To be more productive in everyday life 49.1 46.5 48.5 0.447
To not have burning or watery eyes anymore 48.3 44.7 47.5 0.285
To have fewer side effects 46.9 42.7 45.9 0.207
To feel more comfortable in public 45.3 46.1 45.5 0.818
To feel less burdened in your relationship 44.2 45.9 44.6 0.622
To spend less time on daily treatment 42.8 45.9 43.5 0.357
To feel less tired or groggy 42.6 41.8 42.4 0.804
To have fewer out‑of‑pocket treatment expenses 42.6 35.5 41.0 0.036
To feel less irritated 40.0 36.2 39.1 0.252
To feel less depressed 35.4 34.3 35.1 0.741
To be able to have a normal sex life 32.8 35.3 33.4 0.503
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patients highlighted the importance of a therapy for AR 
in relieving symptoms regardless of the patient group 
and the ease of use. Indeed, SLIT has been shown to be 
effective in adults and pediatric populations with HDM 
allergy across several studies [24, 31–33]. Moreover, use 
of SLIT is easy, non-invasive, painless especially impor-
tant for children, and adapted for administration at home 
[34].
Our survey has some limitations as its design was non-
interventional and observational. A potential bias may 
be found in the selection of patients and results. How-
ever, the strengths of the study conducted in a real-life 
setting with allergy specialists are the large size of the 
analysis population of patients (n =  1589) that may be 
considered the most representative of those suffering 
from HDM allergy and AR in France. This large number 
of patients has enabled the composition of both groups, 
those starting HDM AIT and those selected for other 
therapy, to be stratified by age. Moreover, the data col-
lection used reproducible, standardized and validated 
questionnaires. Finally, this study allowed us to differ-
entiate separate rhinitis clusters by sex, frequency of 
AR symptoms, prescriptions of AIT and symptomatic 
medications, rhinitis severity and QoL. This classifica-
tion may be an additional helpful tool for the physician 
as a complement to severity-based approach using ARIA 
guidelines. In our study, the most severe cluster that 
merits attention was associated with young age of onset 
(median: 27 years), female sex, with frequent and severe 
nasal and ocular symptoms, impaired QoL and frequent 
prescriptions of AIT.
Conclusions
Our study conducted in a real-life setting identified a 
population of patients affected by HDM-AR for at least 
2  years and seen by allergy specialists. The patients 
selected for HDM AIT treatment were characterized by 
the presence of conjunctivitis and asthma. At the time 
Table 6 Characteristics of the different clusters identified
Cluster 1 
N = 854
2 
N = 306
3 
N = 296
p value
Gender (n,  %)
 N available 847 303 292
 Missing 7 3 4
 Male 408 (48.2 %) 167 (55.1 %) 112 (38.4 %) <0.001*
 Female 439 (51.8 %) 136 (44.9 %) 180 (61.6 %)
Age (years)
 N available 840 301 292
 Missing 14 5 4
 Mean ± SD 23.9 ± 13.8 22.0 ± 14.8 26.5 ± 13.4 <0.001**
 Median 22 18 27
 Q1, Q3 12, 33 10, 30 16, 34
 Range 4, 75 5, 70 5, 76
Allergic asthma
 N available 854 306 296
 No 549 (64.3 %) 171 (55.9 %) 179 (60.5 %) 0.030*
 Yes 305 (35.7 %) 135 (44.1 %) 117 (39.5 %)
Severity of AR (ARIA)
 N available 843 305 294
 Missing 11 1 2
 Mild intermittent/
persistent
202 (24.0 %) 216 (70.8 %) 16 (5.4 %) <0.001*
 Moderate to 
severe intermit‑
tent
169 (20.0 %) 32 (10.5 %) 32 (10.9 %)
 Moderate to 
severe persis‑
tent
472 (56.0 %) 57 (18.7 %) 246 (83.7 %)
Levels of AR control (VAS)
 N available 806 285 280
 Missing 48 21 16
 Mean ± SD 4.48 ± 2.67 7.01 ± 2.59 3.76 ± 2.81 <0.001**
 Median 4.2 7.8 2.9
 Q1, Q3 2.3, 6.8 5.6, 9.0 1.5, 6.0
 Range 0.0, 10.0 0.0, 10.0 0.0, 10.0
Physician satisfaction
 N available 766 266 261
 Missing 88 40 35
 Dissatisfied/very 
dissatisfied
493 (64.4 %) 51 (19.2 %) 193 (73.9 %) <0.001*
 Satisfied/very 
satisfied
273 (35.6 %) 215 (80.8 %) 68 (26.1 %)
Patient satisfaction
 N available 808 292 280 <0.001*
 Missing 46 14 16
 Dissatisfied/very 
dissatisfied
463 (57.3 %) 51 (17.5 %) 200 (71.4 %)
 Satisfied/very 
satisfied
345 (42.7 %) 241 (82.5 %) 80 (28.6 %)
ARCT score
 N available 816 294 281
 Missing 38 12 15
Table 6 continued
Cluster 1 
N = 854
2 
N = 306
3 
N = 296
p value
 Mean ± SD 16.6 ± 3.5 21.1 ± 2.8 13.7 ± 4.0 <0.001**
 Median 17 21 13
 Q1, Q3 14, 19 20, 23 11, 16
 Range 5, 25 10, 25 5, 25
Prescription of AIT
 N available 854 306 296
 No 183 (21.4 %) 117 (38.2 %) 51 (17.2 %) <0.001*
 Yes 671 (78.6 %) 189 (61.8 %) 245 (82.8 %)
* Chi squared test, ** Kruskal–Wallis test
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of AIT prescription, over 40 % of patients already expe-
rienced inadequately controlled asthma, and about 60 % 
had mild to severe persistent AR. The major driver of 
AIT prescription was an AR uncontrolled by previous 
medications leading to patient dissatisfaction.
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